Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase 1 Study to Investigate the Safety and Pharmacokinetics of SGN-B6A in Chinese Subjects With Advanced Solid Tumors

NCT06549816 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT06549816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06549816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase 1 Study to Investigate the Safety and Pharmacokinetics of SGN-B6A in Chinese Subjects With Advanced Solid Tumors
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 1
Overall status
Completed
Start date
August 21, 2024
Completion date
November 18, 2025
Enrollment
6 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small cell lung, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, squamous cell carcinoma of head and neck